Thrombolytic therapy for pulmonary embolism

Canadian Journal of Surgery

Volumn 43, Issue 6, 2000, Pages 411-416

  Katchan, B M ^a  

^a NORTH YORK GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT; HEPARIN; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

BLEEDING; BLOOD CLOT LYSIS; DRUG EFFICACY; ECHOCARDIOGRAPHY; FIBRINOLYTIC THERAPY; HEART VENTRICLE FUNCTION; HUMAN; LUNG EMBOLISM; REVIEW; RISK ASSESSMENT; TREATMENT INDICATION;

ACUTE DISEASE; ECHOCARDIOGRAPHY; FIBRINOLYTIC AGENTS; HUMANS; PATIENT SELECTION; PRACTICE GUIDELINES; PULMONARY EMBOLISM; RISK FACTORS; STREPTOKINASE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; URINARY PLASMINOGEN ACTIVATOR; VENTRICULAR DYSFUNCTION, RIGHT;

EID: 0034529531     PISSN: 0008428X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Streptokinase and pulmonary embolism
2. Thrombolytic therapy of pulmonary embolism: A comprehensive review of current evidence
3. Treatment of pulmonary thromboembolism
4. Thrombolytic therapy for pulmonary embolism: Is it effective? Is it safe? When is it indicated?
5. Modern management of pulmonary embolism
6. Pulmonary embolism - An update on thrombolytic therapy
7. Incidence of venous thromboembolism verified by necropsy over 30 years
8. Factors associated with correct antemortem diagnosis of major pulmonary embolism
9. Pulmonary embolism
10. Anticoagulant drugs in the treatment of pulmonary embolism: A controlled trial
11. Acute pulmonary embolism: Clinical outcomes in the International Cooperative Pulmonary Embolism Registry
12. Diagnosis of pulmonary embolism with spiral CT: Comparison with pulmonary angiography and scintigraphy
13. Urokinase pulmonary embolism trial. Phase 1 results: A cooperative study
14. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism
15. PAIMS 2: Alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2
16. Relation of duration of symptoms with response to thrombolytic therapy in pulmonary embolism
17. Streptokinase and heparin versus heparin alone in massive pulmonary embolism: A randomized controlled trial
18. Contemporary pulmonary embolism thrombolysis
19. Pulmonary embolism thrombolysis: Broadening the paradigm for its administration
20. Alteplase versus heparin in acute pulmonary embolism: Randomised trial assessing right-ventricular function and pulmonary perfusion
21. Management strategies and determinants of outcome in acute major pulmonary embolism: Results of a multicenter registry
22. Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism: Results of a multicenter registry
23. Short-term clinical outcome of patients with acute pulmonary embolism, normal blood pressure, and echocardiographic right ventricular dysfunction
24. Urokinase-streptokinase embolism trial. Phase 2 results. A cooperative study
25. Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism
26. Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: A randomized controlled multicenter trial
27. Comparative efficacy of a two-hour regimen of streptokinase versus alteplase in acute massive pulmonary embolism: Immediate clinical and hemodynamic outcome and one-year follow-up
28. Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism
29. Thrombolytic therapy for pulmonary embolism. Frequency of intracranial hemorrhage and associated risk factors